4.8 Article

Understanding pRb: toward the necessary development of targeted treatments for retinoblastoma

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 122, 期 2, 页码 425-434

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI57114

关键词

-

资金

  1. National Ophthalmic Disease Genotyping Network (EyeGENE) NIH/NEI [HHS-N-260-2207-00001-C]
  2. NEI [EY13812, EY02162]
  3. Wayne and Gladys Valley Foundation
  4. That Man May See Foundation Inc.
  5. Research to Prevent Blindness
  6. Jeffrey W. Berger Foundation
  7. Research to Prevent Blindness Inc., New York, New York, USA

向作者/读者索取更多资源

Retinoblastoma is a pediatric retinal tumor initiated by biallelic inactivation of the retinoblastoma gene (RB1). RB1 was the first identified tumor suppressor gene and has defined roles in the regulation of cell cycle progression, DNA replication, and terminal differentiation. However, despite the abundance of work demonstrating the molecular function and identifying binding partners of pRb, the challenge facing molecular biologists and clinical oncologists is how to integrate this vast body of molecular knowledge into the development of targeted therapies for treatment of retinoblastoma. We propose that a more thorough genetic understanding of retinoblastoma would inform targeted treatment decisions and could improve outcomes and quality of life in children affected by this disease.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据